<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Iodixanol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Iodixanol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Iodixanol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12213" href="/d/html/12213.html" rel="external">see "Iodixanol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12989" href="/d/html/12989.html" rel="external">see "Iodixanol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708949"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Not for intrathecal use. Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F183727"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Visipaque</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867219"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Visipaque</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F183730"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Iodinated Contrast Media;</li>
<li>
                        Radiological/Contrast Media (Nonionic, Iso-Osmolality)</li></ul></div>
<div class="block doa drugH1Div" id="F2087667"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4194a5e2-ee40-43cb-9070-747d838c5cbf">Angiocardiography, cerebral arteriography, peripheral arteriography, visceral arteriography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angiocardiography (left ventriculography and selective coronary arteriography), cerebral arteriography, peripheral arteriography, visceral arteriography: Intra-arterial:</b> Iodixanol 320 mg iodine/mL: Dose individualized based on injection site and study type; refer to product labeling. Maximum recommended total dose of iodine: 80 g.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d22ab5b1-bfd8-468c-85f6-e28d7dc16c42">Intra-arterial digital subtraction angiography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-arterial digital subtraction angiography:</b>
<b>Intra-arterial:</b> Iodixanol 270 and 320 mg iodine/mL: Dose individualized based on injection site and study type; refer to product labeling. Maximum recommended total dose of iodine: 80 g.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="221ea43c-386e-454a-afff-57f19b2ebce5">CCTA, CT imaging of the head and body, excretory urography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CCTA, CT imaging of the head and body, excretory urography: IV:</b> Iodixanol 320 mg iodine /mL: Concentration and dose vary based on study type; refer to product labeling. Maximum recommended total dose of iodine: 80 g.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3aa9bc8c-b0cb-420b-ba15-7008a8056758">CT imaging of the head and body, excretory urography, peripheral venography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CT imaging of the head and body, excretory urography, peripheral venography: IV:</b> Iodixanol 270 mg iodine/mL: Concentration and dose vary based on study type; refer to product labeling. Maximum recommended total dose of iodine: 80 g.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990249"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use caution in severe impairment and in setting of combined renal and hepatic disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dialyzable (36% to 49% depending upon the membrane)</p></div>
<div class="block doha drugH1Div" id="F50987401"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with combined hepatic and renal disease.</p></div>
<div class="block doe drugH1Div" id="F2087668"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution.</p></div>
<div class="block dop drugH1Div" id="F2087666"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12989" href="/d/html/12989.html" rel="external">see "Iodixanol: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The concentration and volume of iodixanol to be used should be individualized depending upon age, weight, size of vessel, and rate of blood flow within the vessel. Patients should be adequately hydrated prior to and following iodixanol administration.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="254af187-62ee-45c7-8faf-04c82d95dd9c">Radiologic contrast enhancement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radiologic contrast enhancement: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Angiocardiography, cerebral arteriography, visceral arteriography:</i> Intra-arterial: Iodixanol 320 mg iodine/mL: 1 to 2 mL/kg; maximum dose: 4 mL/kg</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CT imaging of the head and body, excretory urography:</i> IV: Iodixanol 270 mg iodine /mL: 1 to 2 mL/kg; maximum dose: 2 mL/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Angiocardiography (left ventriculography and selective coronary arteriography), cerebral arteriography, peripheral arteriography, visceral arteriography:</i> Intra-arterial: Iodixanol 320 mg iodine/mL: Dose individualized based on injection site and study type; refer to product labeling. Maximum recommended total dose of iodine: 80 <b>g</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Coronary CT angiography (diagnostic): </i>IV: Iodixanol 320 mg iodine /mL: Concentration and dose vary based on study type; refer to product labeling. Maximum recommended total dose of iodine: 80 <b>g</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CT imaging of the head and body, excretory urography:</i> IV: Iodixanol 270 mg iodine/mL or 320 mg iodine/mL: Concentration and dose vary based on study type; refer to product labeling. Maximum recommended total dose of iodine: 80 <b>g</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intra-arterial digital subtraction angiography:</i> Intra-arterial: Iodixanol 270 or 320 mg iodine/mL: Dose individualized based on injection site and study type; refer to product labeling. Maximum recommended total dose of iodine: 80 <b>g</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Peripheral venography:</i> IV: Iodixanol 270 mg iodine/mL: Concentration and dose vary based on study type; refer to product labeling. Maximum recommended total dose of iodine: 80 <b>g</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113910"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (not studied); use caution in severe impairment and in setting of combined renal and hepatic disease. Dialyzable (36% to 49% depending upon the membrane).</p></div>
<div class="block dohp drugH1Div" id="F51113911"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with combined hepatic and renal disease.</p></div>
<div class="block adr drugH1Div" id="F2087646"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Local: Injection site reaction (including cold sensation at injection site, discomfort at injection site, pain at injection site [2%], warm sensation at injection site [29%])</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (≤2%), chest pain (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (≤2%), pruritus (2%), skin rash (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (4%), nausea (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (≤3%), migraine (≤3%), paresthesia (1%), vertigo (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Scotoma (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cardiac arrhythmia, cardiac conduction disorder, edema, flushing, heart failure, hypotension, peripheral ischemia, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatological: Diaphoresis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, dyspepsia, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematological &amp; oncologic: Hematoma</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal sensory symptoms, agitation, altered sense of smell, anxiety, cerebrovascular disease, confusion, dizziness, fatigue, hypoesthesia, insomnia, malaise, nervousness, seizure, stupor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, renal function abnormality</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, bronchitis, dyspnea, pharyngeal edema, pulmonary edema, rhinitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Coronary artery vasospasm, hypertension, palpitations, shock</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, skin discoloration, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperthyroidism, hypothyroidism (premature infants, infants, and children ≤3 years with underlying medical conditions may be more vulnerable; FDA Safety Alert March 30, 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, enlargement of salivary glands, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, coma, impaired consciousness, pain</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual impairment (including blurred vision, cortical blindness, diplopia)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, cough, laryngeal edema, sneezing, throat irritation</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F183721"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal administration</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to iodixanol or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F2087643"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contrast media reactions: Serious and life-threatening hypersensitivity reactions have occurred, including anaphylaxis. Use extreme caution with history of previous reaction to contrast dye, iodine-based contrast media or patients with a known clinical hypersensitivity (eg, bronchial asthma, hay fever, food allergies). Obtain allergy and hypersensitivity history prior to administration. Premedication with antihistamines or corticosteroids should be considered to reduce incidence and severity of reaction. Monitor closely during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatological effects: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to several weeks after administration; reaction severity may increase and time to onset may decrease with repeat administration. Avoid use in patients with a history of a severe cutaneous adverse reaction to iodixanol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: May be a vesicant; ensure proper needle/catheter/line placement prior to and during administration. Monitor infusion site. Avoid extravasation. Extravasation may result in tissue necrosis and/or compartment syndrome, particularly in patients with severe arterial or venous disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal failure: Acute renal failure may occur; has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent. Preparatory dehydration may contribute to acute renal failure in infants, young children and elderly patients, patients with preexisting renal impairment, multiple myeloma, advanced vascular disease, and diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Use meticulous intravascular administration techniques, particularly during angiographic procedures. Ionic iodinated contrast media may inhibit blood coagulation (more than nonionic contrast media). Clotting has been reported when in vitro blood remains in contact with syringes containing nonionic contrast media; use of plastic syringes in place of glass syringes has been reported to decrease, but not eliminate, the likelihood of in vitro clotting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease and heart failure patients receiving concurrent diuretic therapy; they may have intravascular volume depletion, which may affect the renal response to the contrast agent osmotic load; observe such patients for several hours following the procedure to detect renal delayed hemodynamic renal function disturbances. Preparatory dehydration may contribute to acute renal failure in patients with advanced vascular disease; avoid fluid restriction and maintain normal hydration in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Preparatory dehydration may contribute to acute renal failure in patients with diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, and those with concomitant renal impairment, particularly when large doses are administered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Thyroid storm following intravascular administration of iodinated contrast media have occurred in patients with hyperthyroidism or with an autonomously functioning thyroid nodule; use caution in severe thyrotoxicosis. Iodine-binding capacity of thyroid tissue may be reduced for at least 16 days following administration of contrast media for diagnosis of thyroid disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple myeloma: Use with caution in patients with multiple myeloma or other paraproteinacious diseases; use of intravascular contrast agents may lead to renal impairment, especially with concurrent dehydration. Partial dehydration in the preparation of these patients prior to injection is not recommended since this may predispose the patient to precipitation of the myeloma protein.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may worsen myasthenia gravis (MG); use with caution and monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected). Dose injected should be kept to a minimum to minimize exposure; monitor blood pressure closely. Therapy to manage hypertensive crisis should be readily available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary disease: The risks of angiocardiography in patients with chronic pulmonary emphysema should be weighed against the necessity for the procedure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; combined renal and hepatic disease, combined renal and cardiac disease, or anuria; particularly when large doses are administered. Preparatory dehydration may contribute to acute renal failure in patients with preexisting renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sickle cell disease: Use with caution in patients with homozygous sickle cell disease; administration of contrast media may promote sickling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients with age-related renal patients. Preparatory dehydration may contribute to acute renal failure in elderly patients; maintain adequate hydration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Pediatric patients at higher risk of experiencing any adverse events during contrast medium administration may include those having asthma, sensitivity to medication or allergens, heart failure, serum creatinine &gt;1.5 mg/dL, or pediatric patients &lt;12 months of age. Preparatory dehydration may contribute to acute renal failure in infants and young children. Thyroid dysfunction, including transient thyroid suppression or hypothyroidism, has been reported in pediatric patients 0 to 3 years of age following single exposure and multiple exposures to iodinated contrast media; risk increases with younger age, very low birth weight, prematurity, underlying medical conditions affecting thyroid function, neonatal or pediatric intensive care admission, and congenital cardiac conditions (may be greatest risk due to requiring higher doses during invasive cardiac procedures).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate administration: For intravascular use only.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Adequately hydrate patient prior to and following administration. Delay intravenous contrast agent administration in patients who have recently received a cholecystographic contrast agent. In contrast-enhanced computerized tomography, contrast may obscure some lesions previously seen on unenhanced CT scans.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i> Intravascular administration:</i> In angiographic procedures, during catheter manipulations and contrast medium injection, a possibility of dislodging plaques or damaging (or perforating) vessel walls with resultant pseudoaneurysms, hemorrhage at puncture site, or dissection of coronary artery exists. Ensure proper catheter placement with test injections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878500"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use with caution in pediatric patients with asthma, hypersensitivity to other medication and/or allergens, cyanotic and acyanotic heart disease, CHF, serum creatinine &gt;1.5 mg/dL, and neonates (immature renal function) due to an increased risk of adverse effects with iodixanol. Dehydration, particularly in children, may also increase the risk of adverse effects. Patients should be adequately hydrated both prior to and after iodixanol administration. In pediatric patients, apnea, arrhythmias (AV block, bundle branch block), cardiac failure, disseminated intravascular coagulation, and taste perversion have been reported.  </p></div>
<div class="block foc drugH1Div" id="F183718"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Visipaque: Iodine 320 mg/mL (50 mL, 100 mL, 150 mL, 200 mL, 500 mL) [contains edetate (edta) calcium disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Visipaque: Iodine 270 mg/mL (50 mL, 100 mL, 150 mL, 200 mL) [pyrogen free; contains edetate (edta) calcium disodium, tromethamine]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Iodine 270 mg/mL (100 mL, 150 mL); Iodine 320 mg/mL (50 mL, 100 mL, 150 mL, 200 mL)</p></div>
<div class="block geq drugH1Div" id="F183714"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323201"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Iodixanol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">270 mg/mL (per mL): $1.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">320 mg/mL (per mL): $1.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Visipaque Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">270 mg/mL (per mL): $1.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">320 mg/mL (per mL): $1.19</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867220"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Visipaque: Iodine 270 mg/mL (50 mL, 100 mL, 200 mL, 500 mL); Iodine 320 mg/mL (50 mL, 100 mL, 200 mL, 500 mL) [contains edetate (edta) calcium disodium]</p></div>
<div class="block adm drugH1Div" id="F2087670"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Patients should be adequately hydrated prior to and following administration.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">May be a vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid infiltration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CT of head and body:</b> May be used with an automated contrast injection system approved for use with contrast media; iodixanol 320 (100 and 150 mL bottles) may also be used with a contrast management system approved for use with iodixanol; also refer to device instructions. When using contrast media management system, use for one procedure, do not remove bottle from work area once punctured, and do not use for longer than 4 hours from initial puncture; discard any unused portion.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (ACR 2018). Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (ACR 2018); other sources suggest its utility in extravasation management (Belin 2002; Reynolds 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If using hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as five separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Reynolds 2014; Zenk 1981) <b>or</b> injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett 2012).</p></div>
<div class="block admp drugH1Div" id="F52613067"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV or intra-arterial: Administer without further dilution; warm to room temperature or body temperature prior to administration. <b>Not for intrathecal administration</b>.</p>
<p style="text-indent:0em;margin-top:2em;">Patients should be adequately hydrated prior to and following administration.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">May be a vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid infiltration. If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (ACR 2018). Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (ACR 2018); other sources suggest its utility in extravasation management (Bellin 2002; Reynolds 2014) (see Management of Drug Extravasations for more details).</p></div>
<div class="block use drugH1Div" id="F183719"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-arterial:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adults and pediatric patients ≥12 years:</i></p>
<p style="text-indent:-2em;margin-left:6em;">270 and 320 mgI/mL: Intra-arterial digital subtraction angiography.</p>
<p style="text-indent:-2em;margin-left:6em;">320 mgI/mL: Angiocardiography (left ventriculography and selective coronary arteriography); cerebral arteriography; peripheral arteriography; visceral arteriography.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pediatric patients &lt;12 years: </i>320 mgI/mL: Angiocardiography; cerebral arteriography; visceral arteriography.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravenous:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adults and pediatric patients ≥12 years:</i></p>
<p style="text-indent:-2em;margin-left:6em;">270 mgI/mL: Computed tomography (CT) imaging of the head and body; excretory urography; peripheral venography.</p>
<p style="text-indent:-2em;margin-left:6em;">320 mgI/mL: CT imaging of the head and body; excretory urography; coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of patients with suspected coronary artery disease.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pediatric patients &lt;12 years: </i>270 mgI/mL: CT imaging of the head and body; excretory urography.</p></div>
<div class="block mst drugH1Div" id="F2087642"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Not </b>for intrathecal use.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299528"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2087653"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the nephrotoxic effect of Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Iodinated Contrast Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue iodinated contrast agents before sodium iodide I-131 administration, and avoid concurrent use. Stop water soluble agents 2 months before, and stop lipophilic agents 6 months before, sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F183723"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Iodinated contrast media agents may cross the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Due to theoretical concerns that exposure to free iodide may adversely affect the fetus, use should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 723 2017; ACR 2018).</p></div>
<div class="block brc drugH1Div" id="F183724"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Iodine can be detected in breast milk following iodixanol administration (Chruscicki 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant’s GI tract, breastfeeding may be continued without interruption after use (ACOG 723 2017; ACR 2018). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding may express and discard milk from both breasts during a period of 10 to 24 hours after the administration of contrast media. They can pump and store milk prior to the procedure then bottle feed using the stored milk during this time (ACR 2018). According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F45684758"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">Monitor for signs/symptoms of hypersensitivity reactions for ≥30 to 60 minutes; monitor for extravasation during IV administration; blood pressure; dehydration; renal function.</p>
<p style="text-indent:0em;margin-top:2em;">Pediatric patients 0 to 3 years of age: Individualize thyroid function monitoring based on underlying risk factors, especially in term and preterm neonates.</p></div>
<div class="block pha drugH1Div" id="F2087657"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Opacifies vessels in the path of flow permitting radiographic imaging of internal structures.</p></div>
<div class="block phk drugH1Div" id="F2087659"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Note:</b> Following administration, the increase in tissue density is related to blood flow, the concentration of the iodixanol solution used, and the extraction of iodixanol by various interstitial tissues. The degree of enhancement is directly related to the iodine content in an administered dose. </p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Onset of action: Kidney:</p>
<p style="text-indent:-2em;margin-left:4em;">Visualization: Renal parenchyma: 30 to 60 seconds; calyces and pelves (normal renal function): 1 to 3 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Optimum contrast: 5 to 15 minutes</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Distribution: V<sub>d</sub>: 0.26 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: No</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolites have not been demonstrated</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients (Johnson 2001): </p>
<p style="text-indent:-2em;margin-left:6em;">Newborns to Infants &lt;2 months: 4.1 ± 1.4 hours </p>
<p style="text-indent:-2em;margin-left:6em;">Infants 2 to 6 months: 2.8 ± 0.6 hours </p>
<p style="text-indent:-2em;margin-left:6em;">Infants 6 to 12 months: 2.4 ± 0.4 hours </p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to &lt;3 years: 2.2 ± 0.5 hours </p>
<p style="text-indent:-2em;margin-left:6em;">Children 3 to &lt;12 years: 2.3 ± 0.5 hours </p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 2.1 ± 0.1 hours; increased to 23 hours in renal impairment (mean CrCl: 13.61 ± 4.67 mL/minute)  </p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: IV: 0.75 to 1.25 hours </p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Immediate; peak enhancement at 15 to 120 seconds; optimum renal contrast at 5 to 15 minutes; brain contrast at up to 1 hour </p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (97% within 24 hours); feces (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Adults: 110 mL/minute </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038659"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Visipaque</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28937575">
<a name="28937575"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. Erratum in: <i>Obstet Gynecol</i>. 2018;132(3):786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/28937575/pubmed" id="28937575" target="_blank">28937575</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. Version 10.3. 2018. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Last accessed October 17, 2018</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12386778">
<a name="12386778"></a>Bellin MF, Jakobsen JA, Tomassin I, et al; Contrast Media Safety Committee Of The European Society Of Urogenital Radiology. Contrast medium extravasation injury: guidelines for prevention and management. <i>Eur Radiol</i>. 2002;12(11):2807-2812. doi: 10.1007/s00330-002-1630-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/12386778/pubmed" id="12386778" target="_blank">12386778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28680467">
<a name="28680467"></a>Chruscicki A, Morton AR, Akbari A, White CA. Composition of human breast milk in acute kidney injury. <i>Obstet Med</i>. 2017;10(2):79-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/28680467/pubmed" id="28680467" target="_blank">28680467</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  FDA Safety Alert. MedWatch. FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging. Food and Drug Administration website: <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-thyroid-monitoring-babies-and-young-children-who-receive-injections-iodine-containin" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-thyroid-monitoring-babies-and-young-children-who-receive-injections-iodine-containin</a>g. Updated March 30, 2022. Accessed March 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11343148">
<a name="11343148"></a>Johnson WH, Lloyd TR, Victorica BE, et al, “Iodixanol Pharmacokinetics in Children,” <i>Pediatr Cardiol</i>, 2001, 22(3):223-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/11343148/pubmed" id="11343148" target="_blank">11343148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22633726">
<a name="22633726"></a>Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.e1-e3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/22633726/pubmed" id="22633726" target="_blank">22633726</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Visipaque (iodixanol) [prescribing information]. Marlborough, MA: GE Healthcare Inc; April 2023.</div>
</li>
<li>
<div class="reference">
                  Visipaque, Visipaque 270, Visipaque 320 (iodixanol) [product monograph]. Mississauga, Ontario, Canada: GE Healthcare Canada Inc; February 2021.</div>
</li>
<li>
<div class="reference">
                  Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8915 Version 187.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
